News
The French biotechnology firm aims to develop therapies for various neurological conditions using its non-replicating HSV-1 vector technology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback